Yousif Capital Management LLC Increases Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Yousif Capital Management LLC lifted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 8.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,574 shares of the specialty pharmaceutical company’s stock after buying an additional 668 shares during the quarter. Yousif Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $473,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Illinois Municipal Retirement Fund boosted its stake in ANI Pharmaceuticals by 15.3% during the fourth quarter. Illinois Municipal Retirement Fund now owns 9,594 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 1,276 shares in the last quarter. Wedge Capital Management L L P NC grew its stake in shares of ANI Pharmaceuticals by 3.1% in the 4th quarter. Wedge Capital Management L L P NC now owns 65,531 shares of the specialty pharmaceutical company’s stock worth $3,613,000 after buying an additional 1,958 shares during the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $414,000. Allspring Global Investments Holdings LLC increased its position in ANI Pharmaceuticals by 62.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 5,487 shares of the specialty pharmaceutical company’s stock valued at $303,000 after buying an additional 2,107 shares in the last quarter. Finally, New York State Teachers Retirement System raised its stake in ANI Pharmaceuticals by 0.9% during the fourth quarter. New York State Teachers Retirement System now owns 22,380 shares of the specialty pharmaceutical company’s stock valued at $1,234,000 after buying an additional 200 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ANIP shares. Guggenheim reissued a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $80.00.

Insider Activity

In related news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $66.62, for a total transaction of $1,332,400.00. Following the completion of the sale, the senior vice president now owns 233,226 shares in the company, valued at $15,537,516.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, COO Muthusamy Shanmugam sold 7,414 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $66.33, for a total value of $491,770.62. Following the transaction, the chief operating officer now owns 825,206 shares in the company, valued at approximately $54,735,913.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total transaction of $1,332,400.00. Following the sale, the senior vice president now owns 233,226 shares of the company’s stock, valued at $15,537,516.12. The disclosure for this sale can be found here. Insiders have sold 176,803 shares of company stock valued at $11,695,866 in the last ninety days. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $67.25 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 80.06 and a beta of 0.80. The business has a 50-day simple moving average of $66.58 and a two-hundred day simple moving average of $59.18. ANI Pharmaceuticals, Inc. has a fifty-two week low of $37.64 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The company had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.